Form 4: Valion Bio Insider Reports Stock Transactions

Valion Bio, Inc. reports insider transactions involving Chief Financial Officer Lisa G. Wolf acquiring 92 shares of common stock.

Summary

• Lisa G. Wolf, Chief Financial Officer of Valion Bio, Inc., reported a transaction on June 18, 2026.
• Wolf acquired 92 shares of common stock.
• This acquisition brings her total beneficial ownership of common stock to 618 shares.
• The transaction involved Restricted Stock Units (RSUs) that converted into common stock.
• Fifty percent of the RSUs vested on December 18, 2024, with the remainder vesting quarterly over three years from that date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports standard insider stock transactions and vesting schedules without significant positive or negative financial disclosures.

Positives

• Insider acquisition of shares can signal confidence in the company's future prospects.
• The vesting schedule indicates a long-term incentive structure for management.

Future Outlook

The vesting schedule for the remaining Restricted Stock Units indicates a continued commitment and incentive for the Chief Financial Officer over the next three years.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions, are closely watched by the market as they can provide insights into management's perception of the company's valuation and future performance within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the insider's acquisition of stock positively, interpreting it as a sign of confidence in the company's future.

Key Dates

Keywords

Valion Bio, VBIO, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, Beneficial Ownership, Chief Financial Officer